IPO Issue Details
Issue Price / Price Band₹208 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size600 Shares per Lot
Total Issue Size14,53,800 shares (agg. up to ₹30 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh capital only
Exchange / PlatformNSE SME
IPO TypeSME
Subscription OpenThu, 18 Jun 2026
Subscription CloseMon, 22 Jun 2026
Anchor AllotmentWed, 17 Jun 2026
Basis of AllotmentTue, 23 Jun 2026
Initiation of RefundsWed, 24 Jun 2026
Credit of Shares to DematWed, 24 Jun 2026
Listing DateThu, 25 Jun 2026
UPI Mandate Deadline5:00 PM on 22 Jun 2026 (Day 3)
Application & Investment Details
Retail — Min (2 Lots)₹2,49,600 — 1,200 shares
Retail — Max (13 Lots)₹1,622,400 (13 Lots)
HNI — Min (3 Lots)₹3,74,400 — 1,800 shares
EPS (Pre-IPO)₹17.94
EPS (Post-IPO)₹12.56
P/E Ratio (Pre-IPO)11.59x
P/E Ratio (Post-IPO)16.56x
Net Offer to Public13,71,600 shares (agg. up to ₹29 Cr)
Reserved for Market Maker82,200 shares (agg. up to ₹2 Cr)
Pre-IPO Promoter Holding40,31,256 shares
Post-IPO Promoter Holding54,85,056 shares
Fresh Issue Shares13,71,600 shares (agg. up to ₹29 Cr)
About Avience Biomedicals Ltd
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas.In addition to manufacturing, the Company also act as distributors and traders of medical equipment.The company's manufacturing unit is situated in Noida, Uttar Pradesh.The company offers a comprehensive range of diagnostic solutions, including:Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test.Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit.Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY.Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer.Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM).As of January 31, 2026, the company had 75 permanent employees and 33 contractual employeesCompetitive StrengthStrong Industry Experience and Expertise.Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits.Strong distribution network across India and is growing its international footprint.Cost-Effective and Affordable Solutions.Stringent quality control processes and complies with ISO standards and regulatory approvals.
Objects of the Issue
Avience Biomedicals Ltd proposes to utilise the net proceeds from the Issue for the following objects:
1
Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
15.96
2
Funding the working capital requirements of the Company
8.25
3
General Corporate Purposes
Shareholding & Lock-in
Pre-IPO Promoter Holding
40,31,256 shares
Post-IPO Promoter Holding
54,85,056 shares